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Introduction: The activation of the phosphoinositide 3-kinase (PI3K)/AKT signalling pathway is one the most
frequent genetic events in breast cancer, consequently the development of PI3K inhibitors has attracted much
attention. Here we evaluate the effect of PI3K inhibition on global gene expression in breast cancer cells.
Methods: We used a range of methodologies that include in silico compound analysis, in vitro kinase assays, cell
invasion assays, proliferation assays, genome-wide transcription studies (Agilent Technologies full genome arrays),
gene set enrichment analysis, quantitative real-time PCR, immunoblotting in addition to chromatin immunoprecipitation.
Results: We defined the physico-chemical and the biological properties of ETP-45658, a novel potent PI3K inhibitor.
We demonstrated that ETP-45658 potently inhibited cell proliferation within a broad range of human cancer cells, most
potently suppressing the growth of breast cancer cells via inhibiting cell cycle. We show that this response is Forkhead
box O (FOXO) protein dependent and p53 independent. Our genome-wide microarray analysis revealed that the cell
cycle was the most affected biological process after exposure to ETP-45658 (or our control PI3K inhibitor PI-103), that
despite the multiple transcription factors that are regulated by the PI3K/AKT signalling cascade, only the binding sites
for FOXO transcription factors were significantly enriched and only a subset of all FOXO-dependent genes were induced.
This disparity in gene transcription was not due to differential FOXO promoter recruitment.
Conclusions: The constitutive activation of PI3Ks and thus the exclusion of FOXO transcription factors from the nucleus is
a key feature of breast cancer. Our results presented here highlight that PI3K inhibition activates specific FOXO-dependent
genes that mediate cell cycle arrest in breast cancer cells.* Correspondence: walink@ualg.pt
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Breast cancer is the most common and the leading cause of
cancer deaths in women [1]. Similar to other cancers,
breast cancers are extremely heterogeneous with significant
attention directed towards screening and targeting the epi-
dermal growth factor HER2 and the estrogen receptor
alpha. However, in addition to these two molecular targets,
an extremely high percentage of breast cancers are charac-
terized by the constitutive activation of phosphatidylinositol
3-kinases (PI3Ks) [2].
PI3Ks are a family of lipid and protein kinases that are
divided into three classes based on their primary structure
and in vitro substrate specificity [3-5]. The best studied class
I PI3Ks are heterodimeric kinases that are composed of a
catalytic subunit and a regulatory adaptor protein. The acti-
vation of PI3Ks can be triggered by growth factors and insu-
lin that target the PI3K catalytic subunit to the plasma
membrane placing it in close proximity with its substrate
phosphatidylinositol 4,5-bisphosphate (PIP2) [6]. The class I
PI3Ks preferentially phosphorylate PIP2 to generate phos-
phatidylinositol 3,4,5-trisphosphate (PIP3) that as a second-
ary messenger activates the serine/threonine kinase AKT
[7]. The PI3K signalling cascade is controlled by the dual
lipid and protein phosphatase PTEN that negatively regu-
lates the intracellular levels of PIP3 [8]. The constitutive
activation of the PI3K/AKT signalling cascade is very
common in cancer and occurs at different levels typically ei-
ther activating mutations in the genes encoding the kinases
PI3K (PIK3CA) or AKT (AKT1) or the reduced expression
or ablation of the phosphotase PTEN [9-12]. Furthermore
the deregulation of the PI3K/AKT signalling cascade has
been implicated in the deregulation of almost all the aspects
of cell physiology that promotes cell transformation includ-
ing cell cycle progression, enhanced chemotherapeutic
resistance, elevated cell metabolism, increased resistance to
hypoxia and tumour metastasis [12,13]. Many of these pro-
cesses are controlled by the forkhead (FOXO) transcription
family of proteins that bind to a conserved DNA motif
(TTGTTTAC) driving transcription of crucial effecter pro-
teins [14,15]. The FOXO transcription factors are directly
phosphorylated by AKT that promotes their export from
the nucleus-abolishing FOXO-dependent gene transcription,
thus ensuring that FOXO activity is suppressed [16]. Given
the importance of PI3K signalling in breast cancer and the
overwhelming degree of validation for PI3K as a therapeutic
target, it is not surprising that the pharmacological inhib-
ition of PI3Ks are considered to be among the most promis-
ing strategies in drug development for cancer therapy [11].
Consequently a variety of small molecules with different
mechanisms of action (including pan-PI3K, dual PI3K/
mTOR, and isoform-specific PI3K inhibitors) have been
developed and entered a range of clinical trials [5].
We have recently identified pyrazolopyrimidine deriva-
tives as biochemical inhibitors of PI3K and based onthese results, we developed the potent and selective lead
compound ETP-45658 [17]. Here we report our detailed
comparative analysis of the chemical, physical and bio-
logical properties of ETP-45658 and the reference PI3K
inhibitor PI-103 in a broad range of cancer cells particu-
larly breast cancer cells. Furthermore we evaluated and
validated the genome-wide transcriptional changes in
breast cancer cells following exposure to ETP45658 or
PI-103 and demonstrate elucidating the differential
induction of specific FOXO-regulated genes.Material and methods
Cell culture and compounds
Cell lines were obtained from the American Type Culture
Collection (ATTC). U2OS were cultured in Dulbecco’s
modified Eagle’s medium. PC3, MCF7, HCT116, MV4.11
and NCIH460 were grown in RPMI. All media were supple-
mented with 10% foetal bovine serum (Sigma-Aldrich,
St Louis, MO, USA) and antibiotics-antimycotics. The
procedures for the synthesis of ETP-45658 and PI-103
have been described previously [17].Kinase assays
The kinase activity of PI3Kα, PI3Kβ, PI3Kδ and PI3Kγ,
mutant PI3Kα (H1047R and E542K) mammalian target
of rapamycin (mTOR) and DNA-PK was measured as
described previously [17]. The protein kinase assays
depicted in Figure S1 in Additional file 1 and Table S2
in Additional file 2 were performed at ProQinase, GmbH
[18].In silico assessment of physiochemical properties
To calculate the in silico parameters of each compound, we
analysed both agents using PhysChem Batch software
(ACD20, Advanced Chemistry Development, Inc. Version
12 ACD/Labs, Toronto, ON, Canada) that is based on the
quantitative structure-property relationship (QSPR) meth-
odology (including pKa and LogD values).Boyden chamber matrigel invasion assay
Cell-invasive capacity was determined using two-
compartment Boyden chamber matrigel invasion assay
(BD BioCoat™ Matrigel™ Invasion Chambers, BD Bio-
sciences 354480, BD Biosciences, San Jose, CA, USA).
MDA-MB231 cells were allowed to invade for 72 hours at
37°C. All of the inserts and the liquid in each well of the
companion plate were removed. 10% serum RPMI
medium with 5 μM calcein was added to each and incu-
bated for 1 hour (in darkness). Fluorescence was mea-
sured with a luminometer (Envision, PerkinElmer, Inc,
Waltham, MA, USA) at 485/535 nm and the results were
analyzed in Activity Base (IDBS, Guildford, UK).
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Cells were seeded in 96-well microtitre plates. Compounds
(in DMSO) were added to each well (at a final concentra-
tion of 10 μM). The medium was removed from the cells
and replaced with 0.2 ml of medium containing either com-
pound for 72 hours and then processed for MTT assay
(Promega Corp, Madison, WI, USA) N = 6.
Cell cycle analysis
The effect on the cell cycle following treatment with each
compound was assessed by flow cytometry. Cells were
grown to 70% confluence prior to drug treatment (1 to
10 μM) for 24 hours. Cells were stained with 10 μl of propi-
dium iodide (Sigma-Aldrich). A total of 20,000 size gated
cells were analysed by FACSCalibur (BD Biosciences).
Immunoblotting
Sub-confluent cells were incubated under the conditions in-
dicated in each figure and washed twice with phosphate-
buffered saline (PBS) prior to lysis. RIPA lysis buffer was
added (50 mM TrisHCl, 150 mM NaCl, 1% NP-40, 2 mM
Na3VO4, 100 mM NaF, 20 mM Na4P2O7 and 1x protease
inhibitor cocktail (Roche Molecular Biochemicals, Indian-
apolis, IN, USA). The membranes were incubated overnight
for total AKT, phospho-serine-473-AKT, total p53 (DO1)
(Santa Cruz Biotechnology, Dallas, TX, USA), phospho-
threonine 32-FOXO3a (Merck Millipore, Darmstadt,
Germany) and α-tubulin (Sigma-Aldrich). Secondary anti-
bodies used were anti-mouse, goat or rabbit immunoglobu-
lin G (IgG)-horseradish peroxidase (HRP) (Santa Cruz
Biotechnology) as appropriate. Visualisation of bands was
achieved using ChemiDoc imaging system (BioRad Labora-
tories Inc, Hercules, CA, USA) after membrane treatment
with Ecl + (Amersham, Little Chalfont, UK).
Microarray gene expression analysis: RNA amplification
and labelling
Total RNA was prepared from cell lysates using the
RNeasy total RNA Mini kit (Qiagen, Courtaboeuf, France),
according to the manufacturer’s protocol. The amount
and purity of total RNA was determined (NanoDrop,
Thermo Fisher Scientific, Waltham, MA, USA) and the
integrity of the RNA was assessed using a 2100 Bio-
analyzer (Agilent Technologies, Santa Clara, CA, USA).
One-Colour Microarray-Based Gene Expression Analysis
Protocol (Agilent Technologies) was used to amplify and
label RNA. Samples were hybridised to whole human gen-
ome microarray 4 x 44K (G4112F, Agilent Technologies).
For each condition (one control (DMSO) and two treat-
ments (ETP-45658 and PI-103), four replicate hybridisa-
tions were carried out. Arrays were scanned at 5 μm
resolution on an Agilent DNA Microarray Scanner
(G2565BA, Agilent Technologies). Microarray data hasbeen deposited at Gene Expression Omnibus (GEO)
(accession number GSE56579).Microarray data analysis
Data extraction from each array image was carried out
using extraction software provided by Agilent Technolo-
gies. Data analysis was performed in R [19] using various
Bioconductor packages. The background-corrected data
was normalised using the quantile normalisation method
[20]. To identify differences in gene expression between
treated and control samples, the linear models for
microarray data (limma) package [21] was used. P values
were adjusted by utilisation of the Benjamini-Hochberg
(BH) correction methodology [22]. Genes with an
adjusted P value (that is those with a false discovery rate
(FDR) of ≤0.05 and an absolute fold change of ≥1.5)
were considered differentially expressed.Functional enrichment analysis
Two complementary enrichment analysis tools were
applied to our data: standard enrichment analysis (SEA)
[23] of differentially expressed genes and gene set enrich-
ment analysis (GSEA) [24]. SEA for biological processes
(defined in the Gene Ontology database) [25] or pathways
(defined in the KEGG database) [26] as a control reference
was conducted in R using several publically available
Bioconductor resources. The significance of each bio-
logical processes or pathways identified was calculated
using the hypergeometric test (equivalent to Fisher’s exact
test). Complementarily, we carried out GSEA to evaluate
if curated gene sets show statistically significant and con-
cordant differential expression between given conditions
[24]. The curated gene sets used in our GSEA analysis
were obtained from the molecular signature database
(MSigDB) [27]. P values from our SEA and GSEA were
adjusted for multiple testing and converted to FDR using
the BH procedure for SEA or the method implemented in
the GSEA package, respectively [22,24].Chromatin immunoprecipitation (ChIP)
Chromatin immunoprecipitation (ChIP) assays were per-
formed essentially the same as described in [28]. Briefly,
cells were fixed with 1% formaldehyde, and then whole-
cell lysates were prepared. Protein lysate was subjected
to ChIP with the indicated antibodies, followed by DNA
purification (Invitrogen, Waltham, MA, USA). ChIP-
enriched DNA was analyzed by PCR with the indicated
primer sets (Table S1 in Additional file 3) purchased
from NZYTech (Lisbon, Portugal). Visualization of
bands was achieved using a BioRad Chemidoc XRS+
(BioRad) and quantified using the Image Lab software
(BioRad).
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Total RNA was extracted by using Tri-reagent (Sigma-
Aldrich). Real-time PCR was performed on a CFX-96 PCR
machine (BioRad) using the SsoFastSYBR™ green master
mix (BioRad) and following the manufacturer’s guidelines.
The primer sequences for measuring all of our genes of
interest were purchased from NZYTech and are shown in
Table S1 in Additional file 3. Data was analysed as de-
scribed in [29] using the 2-ΔΔCT methodology.
Results
Comparative analysis of the novel PI3K inhibitor
ETP-45658
We have identified pyrazolopyrimidine derivatives as bio-
chemical inhibitors of PI3K including ETP-45658 although
little was known about this compound other than it can in-
hibit PI3K activity [17]. Our first objective was to analyse
the biological activity of ETP-45658 including the physical
and chemical properties of this compound compared to the
reference pan-class I PI3K and mTOR inhibitor PI-103 [9].
We characterised the structure of each compound (Figure
S1A in Additional file 1) and conducted the in silico ana-
lysis of each compound to measure their physiochemical
properties (Figure S1B in Additional file 1). We determined
the molecular polar surface area (PSA) of each compound,
the partition coefficient, the distribution coefficient, com-
pound solubility and the number of hydrogen donors and
acceptors. Our data also indicates that ETP-45658 is more
soluble in aqueous medium at acid pH (compared to PI-
103) although both compounds’ permeability is similar (as
indicated by an equivalent PSA value). Crucially in terms of
drug development and potential development as a novel
therapeutic, ETP-45658 obeys Lipinski’s Rule of Five, sug-
gesting that ETP-45658 could serve as therapeutic agent
[30]. Having determined the key characteristics of ETP-
45658, we evaluated the inhibitory activity of this com-
pound (in comparison to PI-103) against each member of
the PI3K family, including PI3K class 1 isoforms in addition
to distinct p110 mutants. ETP-45658 (and PI-103) inhibited
PI3K and mTOR activity although PI-103 was slightly more
effective against PI3K but significantly less potent at inhibit-
ing mTOR activity compared to ETP-45658 (Figure S1C in
Additional file 1). To develop this analysis further, we ex-
panded this screen and determined the inhibitory activities
of ETP-45658 and PI-103 in a panel of 24 representative
kinases (Figure S1D in Additional file 1). Each indicated
protein kinase activity was assayed following 10 μM treat-
ment with either compound. Of these 24 kinases, only
mutated BRAF was significantly inhibited by either agent,
with an average percent inhibition of 38% following
ETP-45658 treatment (compared to 57.7% following
PI-103 exposure) demonstrating that ETP-45658 is a
potent, highly specific PI3K inhibitor especially when
compared to the reference PI3K inhibitor PI-103.We next wanted to evaluate a range of model in vitro
cancer cell lines to determine their sensitivity to ETP-45658
treatment. We determined the EC50 value for the inhibition
of proliferation in each of the following cell lines, PC3,
MCF7, MV4.11, T47D, HCT-116 and NCIH46 cells. The
inhibitory range for ETP-45658 was between 0.28 μM and
2.96 μM (and between 0.049 μM and 1.76 μM for PI-103)
(Figure 1A). Of all of our tested cell lines, the MCF-7 breast
cancer cell line (containing a K545E PI3K oncogenic muta-
tion) exhibited the highest sensitivity to ETP-45658. To cat-
egorically address the ETP-45658 mode of action (as well
as that of PI-103) we treated MCF-7 cells with either com-
pound for six hours and compared the results with data ob-
tained from experiments using the osteosarcoma cell line
U2OS with a well-characterised PI3K response (Figure 1B).
As early as 30 minutes post treatment with either drug,
there was a significant decrease in phosphorylated serine
473 AKT and by three hours post treatment we were un-
able to detect this post-translational modification in treated
osteosarcoma cells. Regardless of the time point investi-
gated, there was no change in the total AKT protein level
in either the breast or osteosarcoma cell lines. After
observing the reduction and subsequent loss of AKT phos-
phorylation, we questioned if there was the concomitant
downstream signalling cascade to effecter proteins follow-
ing treatment with either compound. Consistent with the
loss of AKT phosphorylation, we note the significant reduc-
tion of serine 253-phosphorylated FOXO3a, a key protein
target that is inhibited by active AKT (Figure 1B). In con-
trast to the rapid loss of AKT phosphorylation, FOXO3a
dephosphorylation was slower. Nevertheless after six hours
post treatment there was an almost complete absence of
this FOXO3a modification in either breast or osteosarcoma
cancer cells. This conserved response to ETP-45658 (and
PI-103) was both temporal and concentration dependent.
The loss of FOXO phosphorylation indicated that AKT
signalling was inhibited, however, it did not demonstrate if
ETP-45658 treatment resulted in the nuclear accumulation
of FOXO3a. To address this question, we collected nuclear
fractions of treated cells at each time point indicated and
conducted immunoblotting for FOXO3a (Figure 1B). Con-
sistent with the inhibition of AKT and the time-dependent
loss of phosphorylated FOXO3a, we detect the significant
accumulation of nuclear FOXO3a. Having observed AKT
inhibition, the loss of an AKT-dependent modification
target and the accumulation of nuclear FOXO3a, we ques-
tioned what the cellular phenotype for the breast or osteo-
sarcoma cells would be after treatment with ETP-45658.
ETP-45658 treatment triggered a potent cell cycle arrest
phenotype characterised by significant G1 and G2 peaks
with little to no S-phase or sub-G1 cell population
(Figure 1C). This cellular response was also noted following
treatment with our reference drug PI-103. Having noted an
arrest response, we examined the effect of ETP-45658 in
Figure 1 (See legend on next page.)
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Figure 1 Cellular response to ETP-45658. (A) Proliferation assay for each indicated cell line treated with serial dilutions of ETP-45658 or reference
compound PI-103. Seventy-two hours post treatment, MTT assays were conducted. (B) Dose- and time-dependent analysis of Ser473 phosphorylation of AKT
phosphorylation by 100nM ETP-45658 or PI-103 treatment. MCF-7 or U2OS cells were treated with the indicated concentrations (μM) of ETP-45658 (or PI-103)
for four hours, then total protein was extracted and immunoblotted. For nuclear FOXO analysis, nuclear protein fractions were collected four hours post
ETP-45658 (or PI-103) treatment. Nuclear FOXO3a levels were measure by immunoblotting. Nuclear fractions were confirmed by probing for lamin A/C. (C)
FACS profile of MCF-7 or U2OS following 100 nM ETP-45658 treatment (20,000 events scored, N = 5). (D) Heat map for the top 100 differentially expressed
genes based on hierarchical clustering using Euclidean distance metric. Red and green indicate genes that induced or repressed respectively by ETP-45658 or
PI-103. Black indicates no change (N = 4). (E) Venn diagram of upregulated genes after ETP-45658 or PI-103 treatment (100nM). (F) Venn diagram of
downregulated genes after ETP-45658 or PI-103 exposure. Numbers indicate number of genes that are exclusive to that particular category.
Hill et al. Breast Cancer Research  (2014) 16:482 Page 6 of 15the well-established breast cancer MDA-MB231 in vitro
cell migration assay. MDA-MB231 cells were grown in a
two-dimensional matrigel transwell chamber and following
treatment with ETP-45658 (or PI-103), cell invasion was
evaluated (Figure S1E in Additional file 1). ETP45658 (and
PI-103) inhibited the capacity of MDA-MB231 cells to mi-
grate through the matrigel without significantly affecting
cell viability, confirming an anti-proliferation rather than an
apoptotic response following PI3K inhibition. Our detailed
analysis defining the physical, chemical and biological prop-
erties indicate the potential of ETP-45658 as a novel thera-
peutic agent with a highly specific mechanism of action
with the strongest potency demonstrated in (although not
exclusively in) breast cancer. These studies enabled us to
define the experimental design for the comparative analysis
for a genome-wide transcriptional study elicited after ETP-
45658 treatment (Figure 1D). We observe a significant glo-
bal transcriptional effect after treatment with ETP-45658
and consistent with this compound (and PI-103) inhibiting
PI3K activity, we note a similar genome-wide expression
profile after treatment with either drug (Additional file 4).
Using a 1.5-fold expression change threshold we identified
2,538 differentially expressed genes after ETP-45658 expos-
ure of which 1,549 genes were induced (Figure 1E) and 989
were repressed (Figure 1F). PI-103 treatment resulted in
1,293 upregulated genes and 886 downregulated genes.
While there were conserved genes that were induced or
repressed by each compound, a number of genes were
differentially affected by each compound. However, consid-
ering the similar phenotype (Figure 1C), the conserved
anti-proliferative effect and the profound effect on global
gene expression after PI3K inhibition upon exposure to
ETP-45658, we directed our attention towards the key
genes that displayed a conserved expression after treatment
between ETP-45658 and the reference compound PI-103.
Identification of functional categories and pathways
enriched in differentially regulated genes
Having noted a potent anti-proliferative effect following
ETP-45658 treatment, we next questioned if there were
conserved signalling cascades or a specific biological process
affected after ETP-45658 treatment. We employed dual SEA
and GSEA (as described in our Materials and methods sec-
tion) identifying the cell cycle and cell cycle-relatedprocesses to be highly enriched in differentially regulated
genes following ETP-45658 treatment (Figure S3A, 3B in
Additional file 5 and Table S2 in Additional file 2) suggest-
ing that the cell cycle is the biological process that is the
most affected after exposure to ETP-45658, a result that is
supported by our FACS analysis shown previously. Inter-
estingly, chromatin modification, DNA damage response
and DNA repair genes were also upregulated following ex-
posure to either compound. Unexpectedly, we note that
pro-apoptotic genes either remained unchanged or were
downregulated after exposure to ETP-45658 (Figure S3A,
S3B in Additional file 5 and Table S3 in Additional file 6).
These results are consistent with our observation that
apoptosis was not the primary response of any of our can-
cer cell lines including our MCF-7 or MDA-MBA231
breast cancer cells after exposure to ETP-45658.
While our results highlight that the primary cellular re-
sponse is an anti-proliferative response (as opposed to an
apoptotic response), for the development of ETP-45658 as
a potential therapeutic, we questioned if ETP-45658 expos-
ure was associated with any degree of toxicity, one of the
most fundamental questions for any proposed therapeutic.
We conducted a genome-wide analysis utilising an Ingenu-
ity Pathway Analysis algorithm to address if any known
toxicity pathway(s) were activated or induced after treat-
ment with ETP-45658 (or by the reference compound PI-
103). This included an extensive evaluation of the cardiac
necrosis stress cascade, genes implicated in kidney failure,
liver necrosis and liver hematomegaly. Furthermore, we
also questioned if, on a genome-wide scale, any know
canonical stress pathways were activated by ETP-45658 (or
PI-103) treatment. This included the p53 pathway, PTEN
aldosterone, ErbB2-ErbB3 and the ERK-MAPK signalling
cascades. Neither ETP-45658 (nor PI-103) treatment sig-
nificantly induced any known toxicity pathways (Figure 2A
and 2B) suggesting that ETP-45658 treatment could be
associated with a highly acceptable toxicity profile, particu-
larly when compared to many chemotherapeutics in use
today.
Transcription factor enrichment analysis
Our data thus far indicates that ETP-45658 (as well as a PI-
103) exerts its effect by inhibiting the cell cycle. However
the PI3K signalling pathway can also direct a plethora of
Figure 2 Focused toxicity and safety assessment of ETP-45658. (A) Analysis of BioFunctions using Ingenuity Pathway Tox Analysis comparing
ETP-45658 vs DMSO (sorted by P value where Y axis represents -log (P value). (B) Analysis of canonical pathways using Ingenuity Pathway Tox
Analysis comparing ETP-45658 vs DMSO (sorted by P value). Y axis represents -log (P value). The line graph indicates the canonical pathway ratio
(number of molecules in a given pathway that meet cut-off criteria, divided by total number of molecules that make up that pathway). None of
the canonical pathways have been identified as significant suggesting little or no toxicity of treatment.
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multiple transcription factors that includes FOXO [16,31],
p53 [32], YAP [33], NFkB [34], CREB [35,36], c-MYC
[37,38], and c-JUN [39]. To address which transcription
factor(s) directed the cellular response to ETP-45658 treat-
ment, we carried out an enrichment analysis for transcrip-
tion factor binding sites based on our genome-wide array
data sets. Our studies identified binding sites for FOXOs,
E12, MAZ, LEF1 and NRF1, to be enriched and consistent
with the toxicity analysis we conducted, we did not observe
any binding site enrichment for p53, NFkB or c-JUN
(Figure 3A). The significant accumulation of FOXO-
dependent genes led us to question if there was an
equivalent enrichment of FOXO-bound DNA motifs. A
transcription factor enrichment analysis demonstrated that
there was a highly significant increase of bound FOXO sites
(Figure 3B). We questioned if the enrichment of these
transcription factors was significant. We calculated P values
for each enriched motif and noted that our P value rangefor these increased motifs were between 8.24E-14 and
5.55E-16, indicating that the increased binding shown in
Figure 3A and 3B was extremely significant.
ETP-45658 treatment triggers FOXO-dependent cell cycle
arrest independent of p53
Having noted a potent cell cycle arrest response following
ETP-455658 (or PI-103) treatment, no enrichment of p53
DNA binding and a significant enrichment of FOXO
transcription factors, we questioned if the cell cycle arrest
response was indeed FOXO dependent and p53 independ-
ent. To address this question, we knocked FOXO3a or p53
down using small interfering RNA (siRNA) in MCF7 and
U2OS cells prior to ETP-45658 treatment (Figure 3C). We
note that 48 hours post exposure to ETP-45658 cells that
did not express FOXO3a show a significantly higher S-
phase cell population and that, in contrast to breast or
osteosarcoma cells that express endogenous levels of
FOXO3a, the absence of a potent cell cycle arrest phenotype
Figure 3 (See legend on next page.)
Hill et al. Breast Cancer Research  (2014) 16:482 Page 8 of 15
(See figure on previous page.)
Figure 3 Transcription factor analysis. (A) Graph of transcription factors enriched in significantly upregulated genes following ETP-45658 treatment.
The white bars indicate the motifs analysed in 3B). (B) Analysis of conserved sequence motifs for FOXO transcription factors (white bars in 3A) showing
the enrichment of FOXO-binding sites within our genome-wide screen. The TRANSFAC matrix table entries for the indicated FOXO-binding sites are
M00472, M00477, M00474 and M00473 respectively. (C) Representative immunoblots showing the effectiveness of FOXO3a or p53 knockdown in
MCF-7 or U2OS cell lines following selection. (D) Cell cycle profile 48 hours post 100 nM ETP-45658 treatment in MCF-7- or U2OS-treated cells, N = 4.
(E) Immunoblot showing little to no p53 accumulation following ETP-45658 exposure. (F) FACS analysis following 100 nM ETP-45658 treatment in
MDA-MB231, Saos2 or (p53−/−) HCT-116 cells N = 4.
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cellular status of p53 had little to no impact regarding the
response to ETP-45658. Following the knockdown of p53
and ETP-45658 treatment, we note that 48 hours post
treatment that there is both a robust G1 and G2 peak in
addition to a significantly reduced S-phase population
(Figure 3D). There was no statistically significant difference
between either scramble or p53-siRNA-treated cells follow-
ing ETP-45658 treatment. As a control, we note that
following 5-fluorouracil (5-FU) treatment, that there is a
potent p53-dependent cell cycle arrest response (independ-
ent of FOXO3a, data not shown). Furthermore and consist-
ent with the absence of an increase of p53-dependent genes
or an enrichment of p53-bound DNA, neither ETP-45658
(nor PI-103) triggered an accumulation of total p53
(Figure 4E). To categorically confirm that the cellular
response is independent of p53, we broadened our study to
include the MDA-MB231 (mutant p53) breast cancer,
Soas2 (p53 null) osteosarcoma and (p53−/−) HCT-116 colon
cancer cell lines. As we predicted, these cell lines show a
potent cell cycle arrest response to ETP-45658 (Figure 3F)
independent of p53. These studies (as well as our invasion
studies shown in Figure S1E in Additional file 1) indicate
that the anti-proliferate response to ETP-45658 (and PI-
103) is FOXO dependent and independent of p53.
After noting the significantly increased level of FOXO re-
cruitment to its consensus sequences after treatment with
ETP-45658 and a significant phenotype change following
the siRNA knockdown of FOXO3a, we analysed our
genome-wide array for all FOXO-dependent genes [39-42].
Strikingly, we note a differential induction of only a subset
of FOXO-regulated genes (Figure 4A). Consistent with the
enrichment of FOXO transcription factors, we observed that
CCNG2, KLHL24, DDIT3, CITED2 and RICTOR were sig-
nificantly upregulated. In contrast CCND1, SPRY2 and
MMP9 expression were significantly downregulated follow-
ing ETP-45658 (or PI-103) treatment. Unexpectedly despite
FOXO dephosphorylation, nuclear accumulation and tran-
scription factor enrichment, the expression of FOXO-
dependent target genes predominantly associated with
FOXO-mediated apoptosis (including TNFSF10, BCL211
and FASLG) did not significantly change after ETP-45658
(or PI-103) exposure (Figure 5A). This was also observed for
the FOXO target genes SOD1 and SOD2 that are known to
be involved in resistance to oxidative stress [43]. Consistentwith this result the most upregulated gene in our entire data
set was cyclin G2 (CCNG2), a FOXO-regulated gene that
encodes an atypical cyclin that blocks cell cycle progression
[44]. In contrast, the most significantly downregulated
FOXO-dependent gene was cyclin D1 (CCND1) a cyclin that
promotes the cell cycle and cell division. Overall our data
indicates that treatment of MCF-7 breast cancer cells with
ETP-45658 directs the differential regulation of a specific
subset of FOXO target genes, specifically targeting those
associated with the cell cycle resulting in the cell cycle arrest
response we observe.
Validation of transcription profiles after ETP-45658 or
PI-103 treatment of breast cancer cells
Our genome-wide array and in vitro studies have eluci-
dated that the predominant pathway activated following
exposure to ETP-45658 (as well as following PI-103 treat-
ment) was FOXO-mediated cell cycle arrest. We showed
the concomitant loss of FOXO phosphorylation, nuclear
FOXO accumulation, the induction of FOXO-regulated
genes, the absence of an arrest phenotype when FOXO3a
was knocked down and have also confirmed that this cell
cycle arrest response was independent of p53. To
strengthen our findings further, we validated our genome-
wide array results by quantitative real-time PCR (qRT-
PCR). Based on our gene expression profiling data, we se-
lected 11 differentially regulated key genes. This included
cyclin G2 (CCNG2), the most induced gene in our array
set and is FOXO regulated, Cbp/p300-interacting transac-
tivator (CITED2), phosphatase and tensin homologue
(PTEN), breast cancer 1, early onset (BRCA1), all three
significantly transcribed after exposure to ETP-45658. We
also selected cyclin D1 (CCND1) that was significantly
downregulated following exposure to ETP-45658. In
addition to these genes, we evaluated tumour necrosis
factor (ligand) superfamily, member 10 (TRAIL), BCL2-
like 11 (BCL2L11), Fas ligand (FASLG) which are FOXO-
dependent genes that do not show any significant
transcriptional change following treatment with ETP-
45658. We selected nischarin (NISCH) as this gene was
significantly induced by ETP-45658 although significantly
downregulated by PI-103 treatment. In our last group, we
selected the cyclin-dependent kinase inhibitor 1A (p21),
which is regulated by both FOXO and p53, BCL2 binding
component 3 (PUMA) and BCL2-associated X (BAX) that
Figure 4 Genes regulated by FOXO transcription factor and validation of key differentially regulated genes. (A) Graph showing FOXO target genes
that are upregulated (log2 fold change≥+1.0) and or downregulated (log2 fold change≤−1.0) following ETP-45658 (or PI-103) treatment in MCF-7 treated
breast cancer cells. Gene expression in MCF-7 breast cancer cells treated at six and twelve hours with (B) 10 nM ETP-45658 or (C) 10 nM PI-103. In each graph,
error bars indicate +/− standard deviation with each gene and condition evaluated in triplicate from N= 3 independent experiments. For each analysis
P values are shown (<0.05 is considered significant).
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treated with ETP-45658 and six or twelve hours post
treatment the total RNA was extracted. We evaluated the
expression profile of each gene (normalised to GAPDH
using the 2-ΔΔCT method described in our Materials and
methods section) (Figure 4B). Consistent with our array
studies we note that there was a highly significant induc-
tion of CCNG2, Cited2 and BRCA1 with the most potentinduction being observed for CCNG2. This response was
conserved between the MCF-7 breast cancer cell line (as we
would predict based on our array studies) as well as the
U2OS osteosarcoma cell line (data not shown). Our qRT-
PCR studies also confirmed that CCND1 transcription was
significantly reduced following ETP-45658 treatment (as
well as after PI-103 exposure). As we would have predicted
from our microarray studies, qRT-PCR analysis detected no
Figure 5 Chromatin immunoprecipitation analysis for FOXO3a promoter recruitment. (A) Chromatin immunoprecipitation (ChIP) assays for
FOXO3a following ETP-45658 treatment at three or six hours of MCF-7 or MDA-MB231 cells for CCG2, CDKN1B, BCL2L11or FASLG. IgG indicates no
specific antibody used and for simplicity, only inputs from our MCF-7 samples are shown. (B and C) Quantification of our ChIP gels normalised to
inputs from each respective cell line. Error bars indicate standard deviation, N = 3.
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tion six hours post ETP-45658 treatment, however, it did
show a slight increase (less than two-fold) in transcription of
each gene at twelve hours post treatment. Interestingly, our
array screen highlighted that, in contrast to PI-103, ETP-
45658 induced the significant transcription of NISCH. This
was also independently validated in our qRT-PCR studies
demonstrating a very strong correlation between our array
data and our qRT-PCR experiments. Consistent with our
data indicating a p53-independent response, there was no
significant induction of any p53-dependent gene we evalu-
ated and conclude that the accumulation of CDKN1A/p21
expression we observe is likely FOXO dependent [45-47].
Taken together, these data indicate that ETP-45658 (and PI-
103), induce a potent FOXO-dependent, p53-independent
cell cycle arrest response, characterised with little to no
FOXO-mediated apoptotic gene induction that was con-
served in breast and osteosarcoma cell lines.
Differential FOXO-dependent gene expression is not due
to ablated promoter binding
Our results highlighted that despite inhibiting AKT, trigger-
ing FOXO nuclear accumulation and mediating a potent
FOXO-dependent cell cycle arrest response, following ETP-
45658 treatment that there is a clear differential expression
profile of FOXO-regulated genes, with little to no pro-
apoptotic FOXO-gene expression in contrast to the robust
expression of FOXO-dependent cell cycle arrest genes. This
led us to hypothesise that this could be the result of differen-
tial FOXO-promoter binding. To answer this question, we
conducted ChIP time courses up to six hours post ETP-
45658 treatment in either MCF-7 or MDA-MB231
breast cancer cells (Figure 5). For this study, we selected
the CCGN2 and cyclin-dependent kinase inhibitor 1B(CDKN1B) cell cycle arrest genes (the first being FOXO
dependent and the most strongly induced gene in our
study while the second encodes a FOXO-dependent cell
cycle arrest protein. We also selected BCL2L11 and
FASLG as both are FOXO-dependent pro-apoptotic
genes that show no significant transcription changes at
six or twelve hours post ETP-45658 exposure. Strik-
ingly, we note that despite the clear differential gene ex-
pression profiles noted between the four genes, there
was statistically significant FOXO3a promoter recruit-
ment for each gene examined by six hours post ETP-
45658 treatment (Figure 5B and 5C). This suggests that
while an absence of FOXO3a promoter binding could
account for the preferential cell cycle arrest gene ex-
pression profile, that this is not the case and that there
is robust pro-apoptotic promoter recruitment. This
suggests that the disparity between cell cycle arrest and
pro-apoptotic FOXO genes arises after FOXO binding.
Discussion
The gene encoding p110α (PIK3CA) is one of the most
commonly mutated kinase in the human genome [9].
Somatic missense mutations in PIK3CA are found in
approximately 15% of all human cancers. In addition
PIK3CA mutations are the most common genetic aberra-
tions observed in breast cancer and occur most frequently
in HER2-amplified and hormone-receptor-positive breast
cancers [48-50]. Given the importance of PI3K anomalies
in breast cancer, the pharmaceutical inhibition of PI3K
has received significant attention. Here we characterise a
novel therapeutic ETP-45658 and report the effect follow-
ing PI3K inhibition on the global gene expression profile
in the MCF-7 model breast cancer cell line that con-
tains an oncogenic missense mutation in PIK3CA. The
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inhibitor of PI3K that directs the nuclear accumulation
of FOXO proteins. We evaluated the key properties of
ETP-45658 (in comparison to the increasingly used ref-
erence PI3K inhibitor PI-103) [9] and show that ETP-
45658 potently inhibited class I PI3Ks and mTOR. The
observation that ETP-45658 is almost three times more
potent than the current reference compound PI-103
against mTOR could be extremely important in a
clinical setting where limited polypharmacology can be
advantageous [51]. Furthermore, mTOR activity has
been shown to be essential for PI3K-dependent onco-
genesis and is involved in feedback activation of PI3K/
AKT signalling via S6 kinase and insulin receptor
substrate-1 [52-54]. As a result compounds that target
both PI3K and mTOR kinase activities at the same time
are thought to inhibit PI3K/AKT signalling more effi-
ciently than selective PI3K inhibitors but could have in-
creased toxicity. Our detailed analysis addressed the
specificity of ETP-45658, analysing the effect in a broad
panel of kinases that represent almost all key families
within the human kinome. The compound PI-103 was
precluded from clinical development due to a number
of significant liabilities that included its limited aqueous
solubility [55]. Crucially, we report that ETP-45658
displays a significantly higher solubility in aqueous
medium at acid pH than PI-103 indicating that ETP-
45658 is considerably more suitable for in vivo experi-
ments (currently underway) and warrants further clin-
ical development. We show that ETP-45658 treatment
resulted in a rapid and potent reduction of AKT phos-
phorylation on serine residue 473 and the concomitant
reduction of FOXO3a phosphorylation. Consistent with
this loss of FOXO3a phosphorylation, we also observed
the significant accumulation of nuclear FOXO3a and
that these responses were conserved in a range of
in vitro cancer models, including MCF-7 and MDA-
MB231 breast cancer cell line models.
Our genome-wide analysis was conducted using MCF-7
breast cancer cells that have been treated with ETP-45658,
PI-103 or DMSO. The MCF-7 cell line is wild-type TP53,
expresses estrogen and progesterone receptors (ER and
PR respectively), and carries a GATA3 frame shift muta-
tion [56]. Microarray gene expression analysis identified
more than 2,000 differentially regulated genes after we
treated our cells with ETP-45658 (or PI-103) reflecting the
major impact of PI3K inhibition on the transcriptional ac-
tivity of genes. The number of conserved genes between
these drugs was 1,760. Given the common mechanism of
action between ETP-45658 and PI-103, this significant
overlap was expected and confirms the consistency of our
experiments. We placed these changes into a biological
framework reporting here that the most significantly af-
fected biological response by ETP-45658 (and PI-103) wasthe cell cycle and cell cycle-related processes. This is in
agreement with our presented data here as well as previ-
ous reports that showed growth arrest occurred in the ab-
sence of apoptosis following glioma cell treatment with
PI-103 or oesteosarcoma cell treatment with ETP-45658
[17,57]. We also asked if any known toxicity or stress
signalling cascades were triggered after exposure to ETP-
45658 and crucially, we note that there was no significant
induction of any of the pathways or cascades that we in-
vestigated. We also showed that binding sites for members
of the FOXO family of transcription factors were highly
enriched in our studies although it remains to be eluci-
dated how PI3K inhibition is so efficient at mediating
FOXO activation in MCF-7 cells that present a low basal
level of AKT activity. Strikingly, upon ETP-45658 treat-
ment MCF-7 (and U2OS) cells only induce a subset of
these FOXO target genes. Specifically, only the cell cycle-
related FOXO-dependent genes presented an altered
transcriptional response, whereas stress resistance or pro-
apoptotic FOXO-dependent genes were found mostly un-
affected by ETP-45658 (or PI-103) treatment. While these
pro-apoptotic genes were not significantly induced, there
was robust FOXO protein recruitment for each gene that
we examined by ChIP, indicating that this transcriptional
response is regulated post-FOXO DNA recruitment.
Hence the interaction with cell or context-specific co-
factors, rather than specific recruitment of FOXO3a to
promoters of cell cycle genes may explain our observa-
tions. This is in agreement with previous studies in which
several co-factors were shown to dictate the transcrip-
tional response to FOXO activation [58]. Importantly, in
colon cancer, high amount of nuclear beta-catenin inter-
acting with FOXO3a has been reported to co-regulate
metastasis-relevant genes upon PI3K/AKT pathway inhib-
ition [59]. Accordingly, PI3K inhibition in breast tumours
with high level of nuclear beta-catenin might promote me-
tastasis. In a recent study, however, beta-catenin was
shown to localise to the plasma membrane and cytoplasm
in MCF7 cells [60]. The identification of specific cofactors
that regulate the FOXO-mediated expression of cell cycle
genes in breast cancer cells remains pertinent for a thor-
ough understanding of FOXO biology.
An important caveat of our studies presented here is
that these experiments only present a global snapshot re-
garding PI3K-regulated gene transcription six hours after
each treatment and does not distinguish between a pri-
mary and secondary transcriptional response. A recent
study by Eijkelenboom et al. suggests that a variation in
overall chromatin architecture between different systems
is responsible for the context-dependent nature of FOXO
activation [40]. The analysis of FOXO-regulated genes in
our data set revealed the cell cycle as the most signifi-
cantly affected biological process by ETP-45658 treatment,
strongly supporting the hypothesis that after the treatment
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mediated by the action of FOXO proteins. Indeed, this is
corroborated by our FACS and proteomic studies that we
present here. In addition, cyclin G2 and cyclin D1 were
among the most upregulated and the most downregulated
genes respectively. Cyclin G2 is suppressed by PI3K/AKT
signalling in proliferating cells [44] while cyclin D1 has been
identified as a target gene downregulated by FOXO and in-
volved in the FOXO-mediated inhibition of cell cycle [61].
Importantly, we confirmed our data for many genes of
interest by qRT-PCR indicating the high accuracy of our ex-
pression profiling studies. Strikingly, with both modalities,
NISCH was found to be significantly upregulated by ETP-
45658 treatment but downregulated after PI-103 treatment.
NISCH has been established recently as a tumour suppres-
sor in breast cancer and has significantly higher expression
in normal breast tissue samples compared to tumour
samples [62]. The therapeutic relevance of this result is
currently under investigation within our laboratory.
As the exclusion of transcriptionally active FOXO proteins
from the nucleus is a key feature of cells that have been
transformed by oncogenic PI3K or AKT the restoration of
FOXO activity has been suggested as a very attractive strat-
egy to treat cancer [31,63]. However, as FOXO factors also
mediate cellular stress resistance, they might also increase
resistance to chemotherapeutics. Therefore, it is crucial to
characterise specific FOXO-dependent transcriptional
programmes in various cell systems to specifically enable the
reactivation of FOXO tumour suppressor functions.
Conclusions
In summary, we show that inhibition of PI3K using differ-
ent small molecule inhibitors potently suppresses the
growth of breast cancer cells via inhibiting cell cycle and
that this response is FOXO protein dependent and p53
independent. Using genome-wide microarray analysis, we
found that FOXO factors are the major downstream tran-
scriptional effectors of PI3K/AKT signalling. However, only
a subset of all FOXO-dependent genes was induced upon
PI3K inhibition. Intriguingly, this was not due to differential
FOXO promoter recruitment, suggesting that the disparity
between cell cycle arrest and pro-apoptotic FOXO target
genes arises after FOXO binding.
Additional files
Additional file 1: Figure S1. Comparative analysis of ETP-45658 and PI-103.
(A) Chemical structure of ETP-45658 and PI-103. (B) Physiochemical properties
of ETP-45658 and PI-103, including molecular polar surface area (PSA), partition
coefficient (LogP), ACD clogD and solubility at two different pH values including
Lipinsky’s Rule of Five (RoF) analysis. (C) Inhibitory activity against PI3K and
mTOR. The kinase activity of PI3K was measured by using the commercial
PI3-kinase HTRF™ assay mTOR activity by LanthaScreen™. (D) ETP-45658 and
PI-103 screen against a panel of 24 kinases. The value shown indicates kinase
inhibition (percentage +/− standard deviation) at 10 μM. (E) Migration ofMDA-MB231 cells in a two compartment Boyden chamber for 72 hours in the
presence of DMSO, ETP-45658 or PI-103 (N = 3).
Additional file 2: Table S2. Ranking analysis of all cell cycle genes. This
table indicates 1,256 cell cycle-related genes following our clustering analysis.
This table includes gene symbols and their corresponding Entrez gene
identities in addition to their averaged log2 fold change and adjusted P values
after analysing gene array data ((ETP-45658 vs DMSO) and (PI-103 vs DMSO);
across all four replicates) using LIMMA.
Additional file 3: Table S1. Primer sequences for quantitative real-time
PCR, siRNA targeting and ChIP assays. This table indicates the complete
5′-3′ sequences for each gene of interest shown. All sequences were
obtained from NZYTech (Lisbon, Portugal).
Additional file 4: Figure S2. Gene expression changes following
ETP-45658 or PI-103 treatment of MCF-7 cells. (A) Volcano plots showing
statistical significance (−log10 P value) plotted against log2 fold change
for either ETP-45658 vs DMSO or PI-103 vs DMSO. Each indicates
significantly overexpressed genes (log2 fold change ≥+1.0, adjusted
P value ≤0.05) in red and downregulated genes (log2 fold
change ≤−1.0, adjusted P value ≤0.05) in green.
Additional file 5: Figure S3. Distribution of differentially regulated
genes that are common to ETP-45658 and PI-103 treatments across
biological processes and pathways. (A) Biological processes that are
significantly represented in upregulated genes. (B) Biological processes
that are enriched in significantly downregulated genes. Number refers to
different regulated genes under each biological process (BP) category.
Note that the BP categories are not exclusive, that is, a gene can be
assigned to several BP categories. The white bars in A and B indicate the
total number of genes within each section (for example the cell cycle);
however, we have also shown specific facets of these processes, for
example, the number of genes involved exclusively in cell cycle arrest).
(C) Biological pathways that are enriched in significantly upregulated
genes. (D) Biological pathways that are represented in significantly
downregulated genes. Number indicates number of differentially
regulated genes assigned to each pathway.
Additional file 6: Table S3. Ranking analysis of key apoptosis genes.
This table shows 1,452 apoptosis-related genes used for our clustering
analysis. The table includes gene symbols, their corresponding Entrez
gene identities, each averaged log2 fold change and their adjusted P
values following the analysis of our gene array studies ((ETP-45658 vs
DMSO) and (PI-103 vs DMSO); across four replicates) using LIMMA.
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